Passage Bio Reports Updated Interim Data From Uplift-D Study
ReutersJun 23, 2025 11:09 AM
June 23 (Reuters) - Passage Bio Inc PASG.O:
PASSAGE BIO REPORTS UPDATED INTERIM DATA FROM UPLIFT-D STUDY AND PROVIDES PROGRAM UPDATE
PASSAGE BIO INC - DOSE 1 PBFT02 SHOWS DURABLE INCREASE IN CSF PGRN LEVELS
PASSAGE BIO INC -REMAIN ON TRACK TO SEEK REGULATORY FEEDBACK ON FTD-GRN PIVOTAL TRIAL DESIGN IN 1H 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
New Fed Chair Warsh Takes Office: Major Shift in Monetary Policy? US Dollar Short-Term Rebound, 2026 Investment Strategy Analysis
TradingKey - At the start of 2026, global financial markets witnessed a major leadership change as U.S. President Trump officially nominated Kevin Warsh as the next Federal Reserve Chair. Pending Senate confirmation, he will succeed Jerome Powell this May to lead the world’s most influential central bank.TradingKey
8 hours ago
Should You Buy Berkshire Hathaway Post-Warren Buffett? What's Warren Buffett's Advice for 2026 Investment?
Berkshire built up a hoard of cash through 2025, accumulating nearly $400 billion—more than it had ever held before. That was by design. Berkshire, instead of joining the artificial intelligence rally that led the headlines, put the cash into short-term U.S. Treasuries with about 3.6% yields.TradingKey
17 hours ago
Digital Asset Rotation: Navigating Market Volatility With the Best Cheap Cryptos for 2026
Navigate the 2026 crypto rotation: Analyze the best cheap cryptos like Solana, Chainlink, and XRP amid Bitcoin’s volatility. Discover top picks for utility and long-term gains.TradingKey
Wed, Feb 18
